MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Mandibular Advancement Device in Parkinson’s disease: an efficacious and usable device in a disabling disease

V. Cochen Decock, M. Castel, I. Bonafé (Montpellier, France)

Meeting: 2019 International Congress

Abstract Number: 1546

Keywords: Excessive daytime sleepiness(EDS), Sleep disorders. See also Restless legs syndrome: Treatment

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Motor Symptoms

Session Time: 1:15pm-2:45pm

Location: Agora 3 West, Level 3

Objective: The aim of our study is to explore the efficacy, observance, and usability of Mandibular Advancement Device in patients with  Parkinson’s disease (PD) and Obstructive Sleep Apnea Syndrome (OSAS).

Background: OSAS is frequent and disturbing in patients with PD. Continuous Positive Airway Pressure (CPAP) is the gold standard treatment of OSAS and its efficacy has already been demonstrated in this peculiar population. However, this treatment is not always well tolerated in this population. Patients have severe maintenance sleep disorders reducing the acceptability of the device. Visuo-spatial disorders disturb their ability to wear their mask alone, increasing the need of help of the caregiver, sometimes repetitively during the night. Mandibular Advancement Device (MAD) is a validated alternative treatment to OSAS in the general population.

Method: Twenty patients with PD and moderate or severe OSAS were included in the study. Ten patients had refused or not tolerated CPAP so that they were treated with MAD. They were matched for sex, age and BMI to ten patients with PD treated with CPAP. We explored the efficacy of MAD on sleep disorders complaints (PDSS-2) and on sleep recordings in these patients. We compared adherence, tolerance and usability of CPAP and MAD in these two groups.

Results: MAD improved sleep disorders on PDSS-2, apnea hypopnea and oxygen desaturation indexes. Observance was much better with MAD than with CPAP. Side effects were similar, but usability and satisfaction of the care giver were much better with MAD than CPAP.

Conclusion: MAD is efficacious, characterized by a good adherence and simple to use in PD with OSAS

To cite this abstract in AMA style:

V. Cochen Decock, M. Castel, I. Bonafé. Mandibular Advancement Device in Parkinson’s disease: an efficacious and usable device in a disabling disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/mandibular-advancement-device-in-parkinsons-disease-an-efficacious-and-usable-device-in-a-disabling-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/mandibular-advancement-device-in-parkinsons-disease-an-efficacious-and-usable-device-in-a-disabling-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley